Organogenesis seeks European approval for Apligraf
This article was originally published in Clinica
Executive Summary
Organogenesis has moved a step closer to marketing its tissue-engineered skin substitute, Apligraf, in Europe, after submitting the product to the European Medicines Evaluation Agency (EMEA).